{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:54:20Z","timestamp":1790632460446,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.coviro.2022.101211","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T07:10:14Z","timestamp":1647501014000},"page":"101211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Broadly neutralizing antibodies against HIV-1 and concepts for application"],"prefix":"10.1016","volume":"54","author":[{"given":"Henning","family":"Gruell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-6800","authenticated-orcid":false,"given":"Philipp","family":"Schommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2022.101211_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2022.101211_bib0010","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101211_bib0015","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/v11040384","article-title":"Lower broadly neutralizing antibody responses in female versus male HIV-1 infected injecting drug users","volume":"11","author":"Euler","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2022.101211_bib0025","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1172\/JCI139123","article-title":"SIV infection duration largely determines broadening of neutralizing antibody response in macaques","volume":"130","author":"Wu","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2022.101211_bib0030","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62648","article-title":"Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth","volume":"10","author":"Cizmeci","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.coviro.2022.101211_bib0035","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101211_bib0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41586-018-0517-0","article-title":"Tracing HIV-1 strains that imprint broadly neutralizing antibody responses","volume":"561","author":"Kouyos","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101211_sbref0045","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd2638","article-title":"Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth","volume":"371","author":"Roark","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101211_sbref0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41590-019-0581-0","article-title":"Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth","volume":"21","author":"Roskin","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2022.101211_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0381","article-title":"The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen","volume":"10","author":"Havenar-Daughton","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0060","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax4380","article-title":"A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101211_bib0065","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41596-021-00554-w","article-title":"Effective high-throughput isolation of fully human antibodies targeting infectious pathogens","volume":"16","author":"Gieselmann","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.coviro.2022.101211_sbref0070","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cell.2019.11.003","article-title":"High-throughput mapping of B cell receptor sequences to antigen specificity","volume":"179","author":"Setliff","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101211_bib0075","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101211_bib0080","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and broad HIV-neutralizing antibodies in memory B cells and plasma","volume":"2","author":"Williams","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2022.101211_sbref0085","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101211_bib0090","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2019.02.008","article-title":"Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual","volume":"50","author":"Krebs","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101211_bib0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12973-1","article-title":"An MPER antibody neutralizes HIV-1 using germline features shared among donors","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101211_bib0100","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","article-title":"Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01","volume":"26","author":"Pinto","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101211_bib0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb1328","article-title":"A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite","volume":"6","author":"Kumar","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2022.101211_sbref0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101211_bib0115","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01274-21","article-title":"Near-Pan-neutralizing, plasma deconvoluted antibody N49P6 mimics host receptor CD4 in its quaternary interactions with the HIV-1 envelope trimer","volume":"12","author":"Tolbert","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2022.101211_bib0120","article-title":"Improvement of antibody functionality by structure-guided paratope engraftment","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101211_bib0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.immuni.2018.02.013","article-title":"A neutralizing antibody recognizing primarily N-linked glycan targets the silent face of the HIV envelope","volume":"48","author":"Zhou","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101211_sbref0130","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.immuni.2019.04.014","article-title":"Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope","volume":"50","author":"Schoofs","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101211_bib0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101211_bib0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101211_bib0150","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201214","article-title":"Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia","volume":"218","author":"Nishimura","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0155","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01743-21","article-title":"Revisiting an IgG Fc loss-of-function experiment: the role of complement in HIV broadly neutralizing antibody b12 activity","volume":"12","author":"Goldberg","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2022.101211_bib0160","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201949351","article-title":"Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells","volume":"21","author":"Dufloo","year":"2020","journal-title":"EMBO Rep"},{"key":"10.1016\/j.coviro.2022.101211_bib0165","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1172\/JCI135557","article-title":"Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies","volume":"130","author":"Tuyishime","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2022.101211_bib0170","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01808-20","article-title":"Relationships between neutralization, binding, and ADCC of broadly neutralizing antibodies against reservoir HIV","volume":"95","author":"Ren","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101211_sbref0175","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2022.101211_sbref0180","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2022.101211_bib0185","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2022.101211_bib0190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates","volume":"13","author":"Hangartner","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2022.101211_sbref0200","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study","volume":"14","author":"Cohen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2022.101211_bib0210","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coviro.2022.101211_bib0215","series-title":"Abstract 508, Conference on Retroviruses and Opportunistic Infections 2020","article-title":"A phase I dose escalation-trial of human monoclonal antibody N6LS in healthy adults","author":"Widge","year":"2020"},{"key":"10.1016\/j.coviro.2022.101211_sbref0220","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiab229","article-title":"Safety, tolerability, and pharmacokinetics of a long-acting broadly neutralizing human immunodeficiency virus type 1 (HIV-1) monoclonal antibody VRC01LS in HIV-1-exposed newborn infants","volume":"224","author":"McFarland","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101211_bib0225","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/jiz532","article-title":"Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants","volume":"222","author":"Cunningham","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101211_bib0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13972-y","article-title":"Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity","volume":"11","author":"Shapiro","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101211_bib0235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2022.101211_bib0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0245","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coviro.2022.101211_bib0250","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101211_bib0260","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrmicro1477","article-title":"Bioinformatics-assisted anti-HIV therapy","volume":"4","author":"Lengauer","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2022.101211_bib0265","series-title":"HIV Drug Resistance Report 2021","author":"WHO","year":"2021"},{"key":"10.1016\/j.coviro.2022.101211_bib0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-015-0148-6","article-title":"An integrated map of HIV genome-wide variation from a population perspective","volume":"12","author":"Li","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2022.101211_bib0275","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101211_bib0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50635-w","article-title":"Accurate prediction for antibody resistance of clinical HIV-1 isolates","volume":"9","author":"Rawi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2022.101211_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005789","article-title":"Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time","volume":"13","author":"Hake","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.coviro.2022.101211_bib0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000002722","article-title":"Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials","volume":"88","author":"Moldt","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2022.101211_bib0295","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130153","article-title":"Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir","volume":"4","author":"Yu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.coviro.2022.101211_bib0300","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.immuni.2018.12.017","article-title":"An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes","volume":"50","author":"Dingens","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101211_bib0305","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1845908","article-title":"Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice","volume":"12","author":"van der Velden","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.coviro.2022.101211_bib0310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101211_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009339","article-title":"TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption","volume":"17","author":"Hsu","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101211_sbref0320","first-page":"856","article-title":"Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat","volume":"25","author":"Gay","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101211_bib0325","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.coviro.2022.101211_bib0330","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101211_bib0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16928-9","article-title":"Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies","volume":"11","author":"Garber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101211_bib0340","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146975","article-title":"Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge","volume":"131","author":"Astronomo","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2022.101211_sbref0345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101211_bib0350","article-title":"Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates","volume":"95","author":"Lorenzi","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101211_bib0355","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101211_sbref0360","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:05:02Z","timestamp":1761818702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625722000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":72,"alternative-id":["S1879625722000207"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101211","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadly neutralizing antibodies against HIV-1 and concepts for application","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101211"}}